Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
31 July 2008 - 9:30PM
PR Newswire (US)
JERUSALEM, July 31 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP) (http://www.oramed.com/), a
developer of oral delivery systems, announced today that it will
hold a conference call on August 6, 2008 at 10:30 AM EDT to present
the results of its Phase 2A clinical trials of its flagship
product, ORMD 0801, an oral insulin capsule. Oramed's Phase 2A
trial is focused on assessing the safety and efficacy of ORMD 0801.
This study is a continuation of the successfully completed Phase 1
studies in Israel. Interested parties should dial: In the United
States: +1-888-668-9141 All other locations: +972-3-918-0691 About
Oramed Pharmaceuticals Oramed Pharmaceuticals is a technology
pioneer in the field of oral delivery solutions for drugs and
vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented
flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology
is based on over 25 years of research by top research scientists at
Jerusalem's Hadassah Medical Center. The Company's corporate and
R&D headquarters are based in Jerusalem. For more information,
please visit http://www.oramed.com/ Forward-looking statements Some
of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements. Company and Investor
Relation Contacts: Oramed Pharmaceuticals Eric Rosenberg Cell:
+972-54-566-7713 Office: +972-2-566-0001 Media Contacts: Ruder Finn
Israel for Oramed Matthew Krieger Cell: +972-54-467-6950 Office:
+972-2-589-2003 DATASOURCE: Oramed Pharmaceuticals Inc. CONTACT:
Company and Investor Relation Contacts: Oramed Pharmaceuticals,
Eric Rosenberg, Cell: +972-54-566-7713, Office: +972-2-566-0001, ;
Media Contacts: Ruder Finn Israel for Oramed, Matthew Krieger,
Cell: +972-54-467-6950, Office: +972-2-589-2003,
Copyright